MedTrace Logo

The Efficacy of Glucerna SR in Chinese Drug-naïve Subjects With Type 2 Diabetes

NCT02248714 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2019-07-01

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the effect of Glucerna SR treating newly-diagnosed type 2 diabetes patients (NDM) on glycemic stability, with the application of CGMS (continuous glucose monitoring system) and to further realize the safety and effect of Glucerna SR on daily and day-to-day amplitude of blood glucose fluctuation.

Conditions

Interventions

DIETARY_SUPPLEMENT

Glucerna SR

Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response.

Sponsors & Collaborators

  • Shanghai Jiao Tong University Affiliated Sixth People's Hospital

    lead OTHER

Principal Investigators

  • Yuqian Bao, MD · Shanghai Jiao Tong University Affiliated Sixth People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2018-06-30
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02248714 on ClinicalTrials.gov